<DOC>
	<DOCNO>NCT02887625</DOCNO>
	<brief_summary>To compare efficacy , safety durability combination therapy pioglitazone plus GLP-1 RA versus basal bolus insulin poorly control T2DM patient metformin plus sulfonylurea</brief_summary>
	<brief_title>Exenatide Plus Pioglitazone Versus Insulin Poorly Controlled T2DM</brief_title>
	<detailed_description>poorly control ( HbA1c &gt; 7.5 % ) T2DM patient ( 18-75 year age ) maximal/near maximal dose sulfonylurea plus metformin otherwise healthy randomize receive : 1. exenatide weekly injection ( 2 mg/week ) 2. glargine insulin plus insulin aspart titrate maintain HbA1c &lt; 7.0 %</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>T2DM poorly control ( HbA1c &gt; 7.5 % ) metformin ( &gt; 1700 mg/day ) plus sulfonylurea type 1 diabetes ( T1DM ) patient receive therapy pioglitazone , GLP1 RA insulin abnormal kidney , liver heart function patient malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>